Literature DB >> 16885381

Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole.

Luciana F Macedo1, Zhiyong Guo, Syreeta L Tilghman, Gauri J Sabnis, Yun Qiu, Angela Brodie.   

Abstract

Previous work has shown that androgens inhibit breast cancer cells and tumor growth. On the other hand, androgens can be converted to mitogenic estrogens by aromatase in breast cancer cells. Here, we report that androgens, such as the aromatizable androstenedione and the non-aromatizable 5alpha-dihydrotestosterone, inhibit MCF-7 cell proliferation. This effect is observed only in the absence or at a low concentration of estrogens and is evident in cells with low aromatase activity. Growth of a new aromatase stably transfected MCF-7 cell line (Ac1) was stimulated by conversion of androstenedione into estrogens and was sensitive to aromatase inhibitors. We show that blockade of the androgen receptor (AR) in these cells by the antiandrogen casodex or by the anti-AR small interfering RNA inhibited the antiproliferative effect of dihydrotestosterone and letrozole (aromatase inhibitor). We also show that suppression of the estrogen-induced antiapoptotic protein Bcl-2 may be involved in the antiproliferative effects of androgens and letrozole. These effects can be reversed by casodex. In conclusion, the results suggest that aromatase inhibitors may exert their antiproliferative effect not only by reducing the intracellular production of estrogens but also by unmasking the inhibitory effect of androgens acting via the AR.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16885381     DOI: 10.1158/0008-5472.CAN-05-3984

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  52 in total

1.  The effect of physiological concentrations of sex hormones, insulin, and glucagon on growth of breast and prostate cells supplemented with unmodified human serum.

Authors:  Amin Esfahani; Cyril W C Kendall; Balachandran Bashyam; Michael C Archer; David J A Jenkins
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-10-07       Impact factor: 2.416

2.  Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

Authors:  Xiaonan Hou; Fei Huang; Luciana F Macedo; Sean C Harrington; Karen A Reeves; Ann Greer; Friedrich Graf Finckenstein; Angela Brodie; Marco M Gottardis; Joan M Carboni; Paul Haluska
Journal:  Cancer Res       Date:  2011-10-31       Impact factor: 12.701

Review 3.  Targeting the androgen receptor in breast cancer.

Authors:  KeeMing Chia; Megan O'Brien; Myles Brown; Elgene Lim
Journal:  Curr Oncol Rep       Date:  2015-02       Impact factor: 5.075

4.  Endocrine disruptors fludioxonil and fenhexamid stimulate miR-21 expression in breast cancer cells.

Authors:  Yun Teng; Tissa T Manavalan; Chuan Hu; Svjetlana Medjakovic; Alois Jungbauer; Carolyn M Klinge
Journal:  Toxicol Sci       Date:  2012-10-10       Impact factor: 4.849

Review 5.  Androgens in human breast carcinoma.

Authors:  Takashi Suzuki; Yasuhiro Miki; Kiyoshi Takagi; Hisashi Hirakawa; Takuya Moriya; Noriaki Ohuchi; Hironobu Sasano
Journal:  Med Mol Morphol       Date:  2010-08-04       Impact factor: 2.309

6.  Importance of Breast Cancer Subtype in the Development of Androgen Receptor Directed Therapy.

Authors:  Elgene Lim; Min Ni; Shiliang Cao; Aditi Hazra; Rulla M Tamimi; Myles Brown
Journal:  Curr Breast Cancer Rep       Date:  2014-06-01

7.  Pre-diagnostic sex hormone levels and survival among breast cancer patients.

Authors:  Kevin H Kensler; A Heather Eliassen; Bernard A Rosner; Susan E Hankinson; Myles Brown; Rulla M Tamimi
Journal:  Breast Cancer Res Treat       Date:  2019-01-02       Impact factor: 4.872

8.  Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.

Authors:  James N Ingle; Fang Xie; Matthew J Ellis; Paul E Goss; Lois E Shepherd; Judith-Anne W Chapman; Bingshu E Chen; Michiaki Kubo; Yoichi Furukawa; Yukihide Momozawa; Vered Stearns; Kathleen I Pritchard; Poulami Barman; Erin E Carlson; Matthew P Goetz; Richard M Weinshilboum; Krishna R Kalari; Liewei Wang
Journal:  Cancer Res       Date:  2016-10-10       Impact factor: 12.701

9.  Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element.

Authors:  Marilena Lanzino; Diego Sisci; Catia Morelli; Cecilia Garofalo; Stefania Catalano; Ivan Casaburi; Claudia Capparelli; Cinzia Giordano; Francesca Giordano; Marcello Maggiolini; Sebastiano Andò
Journal:  Nucleic Acids Res       Date:  2010-04-26       Impact factor: 16.971

Review 10.  Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?

Authors:  T E Hickey; J L L Robinson; J S Carroll; W D Tilley
Journal:  Mol Endocrinol       Date:  2012-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.